Recombinant human growth factor for periodontal regeneration may be efficacious
Satheesh Elangovan, BDS, ScD, DMSc
Systematic Review Conclusion
Limited evidence suggests that recombinant human platelet–derived growth factor-BB (rhPDGF-BB) may improve periodontal outcomes in the short term.
Critical Summary Assessment
Based on the limited evidence from the meta-analysis
of 2 short-term randomized controlled trials, rhPDGF-BB led to statistically significant short-term clinical difference in attachment gain and percentage of bone fill, with rhPDGF-BB in combination with beta-tricalcium phosphate (ß-TCP) in periodontal defects, compared with defects treated with ß-TCP alone. However, considering the minimal absolute improvement and the significant added cost to the patient, the routine use of rhPDGF-BB over conventional techniques may not be justified.
Evidence Quality Rating
This summary is published in the Journal of the American Dental Association and can be accessed at:
Critical Summary Publication Date:
These summaries are not intended to, and do not, express, imply, or summarize standards of care, but rather provide a concise reference for dentists to aid in understanding and applying evidence from the referenced systematic review in making clinically sound decisions as guided by their clinical judgment and by patient needs. American Dental Association © 2019